What is Inmed Pharmaceuticals Inc's earnings per share (EPS)?

Inmed Pharmaceuticals Inc (INM) reported diluted earnings per share of $-8.36 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inmed Pharmaceuticals Inc Financials

INM

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE June

This page shows Inmed Pharmaceuticals Inc (INM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INM FY2025 2026-05-06

Fresh financing, not product sales, is sustaining the business while the cost base remains structurally larger than revenue.

From FY2023 to FY2025, cash climbed from $8.9M to $11.1M. That happened despite about $22M of cumulative operating cash burn over the same span, showing liquidity was rebuilt by financing rather than by cash-generating operations; the cash balance currently says more about capital access than about a self-funding model.

FY2025 gross margin recovered to 34.5% from 23.9%, so the direct economics of each sales dollar improved. But overhead scale still dominates: SG&A was $6.6M against revenue of $4.9M, making this look more like a fixed operating structure problem than a product-margin problem.

The balance sheet is lightly obligated and equity-funded: cash of $11.1M exceeded total liabilities of $2.1M, so near-term pressure comes more from burn than from creditors. Compared with FY2023, spending mix has tilted away from R&D and toward corporate overhead, which helps explain why losses stayed deep even as sales edged higher and gross margin recovered.

Financial Health Signals

Financial Health Score 64/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Inmed Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Piotroski F-Score Partial

4/8

Inmed Pharmaceuticals Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.95x

For every $1 of reported earnings, Inmed Pharmaceuticals Inc generates $0.95 in operating cash flow (-$7.8M OCF vs -$8.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.9M

YoY+7.5%

Inmed Pharmaceuticals Inc generated $4.9M in revenue in fiscal year 2025. This represents an increase of 7.5% from the prior year.

EBITDA

N/A

Net Income

-$8.2M

YoY-6.3%

Inmed Pharmaceuticals Inc reported -$8.2M in net income in fiscal year 2025. This represents a decrease of 6.3% from the prior year.

EPS (Diluted)

$-8.36

Inmed Pharmaceuticals Inc earned $-8.36 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$7.8M

YoY-11.0%

Inmed Pharmaceuticals Inc generated -$7.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 11.0% from the prior year.

Cash & Debt

$10.7M

YoY+63.5%

5Y CAGR+13.1%

Inmed Pharmaceuticals Inc held $10.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Inmed Pharmaceuticals Inc had 2M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

34.5%

YoY+10.6pp

Inmed Pharmaceuticals Inc's gross margin was 34.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.6 percentage points from the prior year.

Operating Margin

N/A

Net Margin

-165.1%

YoY+1.8pp

Inmed Pharmaceuticals Inc's net profit margin was -165.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.8 percentage points from the prior year.

Return on Equity

-60.8%

YoY+22.6pp

5Y CAGR+91.3pp

Inmed Pharmaceuticals Inc's ROE was -60.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 22.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.9M

YoY-11.3%

5Y CAGR-13.3%

Inmed Pharmaceuticals Inc invested $2.9M in research and development in fiscal year 2025. This represents a decrease of 11.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Inmed Pharmaceuticals Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

INM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.9M+7.5%	$4.6M+11.2%	$4.1M+279.6%	$1.1M-42.8%	$1.9M	N/A
Cost of Revenue	$3.2M-7.5%	$3.5M+28.0%	$2.7M+400.6%	$546K	N/A	N/A
Gross Profit	$1.7M+55.0%	$1.1M-21.5%	$1.4M+158.1%	$544K	N/A	N/A
R&D Expenses	$2.9M-11.3%	$3.2M-13.8%	$3.7M-48.8%	$7.3M+36.4%	$5.3M-8.1%	$5.8M
SG&A Expenses	$6.6M+13.1%	$5.8M-0.8%	$5.8M-14.8%	$6.9M+53.3%	$4.5M+38.8%	$3.2M
Operating Income	N/A	N/A	-$7.9M+57.3%	-$18.6M-82.3%	-$10.2M	N/A
Interest Expense	N/A	N/A	N/A	N/A	-$360K	N/A
Income Tax	N/A	$7K-45.8%	$13K	N/A	N/A	N/A
Net Income	-$8.2M-6.3%	-$7.7M+3.4%	-$7.9M+57.3%	-$18.6M-82.3%	-$10.2M-14.1%	-$8.9M
EPS (Diluted)	$-8.36	$-20.14	$-3.25+90.2%	$-33.17+12.6%	$-37.96	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	N/A	$820K-26.8%	$1.1M-14.1%	$1.3M+3.4%	$1.3M+13.5%	$1.1M-12.1%	$1.3M-1.4%	$1.3M
Cost of Revenue	N/A	$636K-11.3%	$717K-1.5%	$728K-33.0%	$1.1M+66.9%	$651K-15.6%	$771K-28.6%	$1.1M
Gross Profit	N/A	$184K-54.3%	$403K-30.1%	$577K+228.3%	$176K-61.9%	$461K-6.6%	$493K+5.9%	$466K
R&D Expenses	$1.0M+62.2%	$631K+8.4%	$582K-30.2%	$833K+95.9%	$425K-52.5%	$895K+27.9%	$700K+6.3%	$659K
SG&A Expenses	$1.7M+7.5%	$1.6M+5.8%	$1.5M-13.0%	$1.8M+11.2%	$1.6M-7.8%	$1.7M+15.1%	$1.5M-15.2%	$1.8M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.0M-46.3%	-$2.0M-17.4%	-$1.7M+3.4%	-$1.8M+15.7%	-$2.1M+17.6%	-$2.6M-53.5%	-$1.7M+13.4%	-$1.9M
EPS (Diluted)	$-0.73-43.1%	$-0.51-15.9%	$-0.44	N/A	$-1.94+46.7%	$-3.64	$-2.71	N/A

INM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.6M+31.8%	$11.8M-16.2%	$14.1M+10.3%	$12.8M+30.7%	$9.8M+25.4%	$7.8M
Current Assets	$12.9M+48.1%	$8.7M-23.3%	$11.3M+18.1%	$9.6M+14.6%	$8.4M+32.7%	$6.3M
Cash & Equivalents	$10.7M+63.5%	$6.6M-26.3%	$8.9M+44.3%	$6.2M-16.1%	$7.4M+26.8%	$5.8M
Inventory	$961K-22.8%	$1.2M-23.0%	$1.6M-35.1%	$2.5M	N/A	N/A
Accounts Receivable	$465K+31.8%	$353K+35.5%	$260K+195.8%	$88K+638.5%	$12K-73.7%	$45K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.1M-18.0%	$2.6M+29.8%	$2.0M-45.6%	$3.7M+54.2%	$2.4M+25.0%	$1.9M
Current Liabilities	$1.8M-6.7%	$2.0M-1.4%	$2.0M-39.7%	$3.3M+49.8%	$2.2M+32.2%	$1.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$13.4M+45.9%	$9.2M-23.9%	$12.1M+33.2%	$9.1M+23.1%	$7.4M+25.5%	$5.9M
Retained Earnings	-$117.2M-7.5%	-$109.1M-7.6%	-$101.4M-8.5%	-$93.5M-24.8%	-$74.9M-15.8%	-$64.6M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$9.1M-18.4%	$11.2M-16.2%	$13.4M-14.2%	$15.6M+67.9%	$9.3M+9.1%	$8.5M-18.8%	$10.5M-11.5%	$11.8M
Current Assets	$6.9M-21.6%	$8.8M-18.6%	$10.8M-16.1%	$12.9M+100.7%	$6.4M+17.2%	$5.5M-24.9%	$7.3M-16.2%	$8.7M
Cash & Equivalents	$5.2M-25.8%	$7.0M-25.5%	$9.3M-13.1%	$10.7M+129.6%	$4.7M+36.9%	$3.4M-38.8%	$5.6M-15.0%	$6.6M
Inventory	N/A	$948K+6.4%	$891K-7.3%	$961K+18.1%	$814K-26.2%	$1.1M-9.6%	$1.2M-1.9%	$1.2M
Accounts Receivable	N/A	$183K-46.7%	$343K-26.2%	$465K+26.5%	$368K+40.1%	$263K-7.8%	$285K-19.3%	$353K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M+39.8%	$1.6M-9.4%	$1.8M-17.5%	$2.1M-5.0%	$2.3M-2.7%	$2.3M+12.1%	$2.1M-20.9%	$2.6M
Current Liabilities	$2.2M+49.4%	$1.5M-4.8%	$1.6M-15.5%	$1.8M0.0%	$1.8M+2.7%	$1.8M+24.7%	$1.4M-27.2%	$2.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.9M-28.1%	$9.6M-17.3%	$11.6M-13.7%	$13.4M+91.3%	$7.0M+13.6%	$6.2M-26.4%	$8.4M-8.8%	$9.2M
Retained Earnings	-$124.0M-2.5%	-$121.0M-1.7%	-$119.0M-1.5%	-$117.2M-1.5%	-$115.4M-1.9%	-$113.3M-2.3%	-$110.8M-1.5%	-$109.1M

INM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.8M-11.2%	-$7.0M+4.1%	-$7.3M+53.3%	-$15.6M-59.2%	-$9.8M-32.8%	-$7.4M
Capital Expenditures	$0-100.0%	$9K-94.2%	$160K+309.2%	$39K+2167.1%	$2K-95.9%	$43K
Free Cash Flow	-$7.8M-11.0%	-$7.0M+6.0%	-$7.4M+52.4%	-$15.6M-59.5%	-$9.8M-32.0%	-$7.4M
Investing Cash Flow	$0+100.0%	-$9K+98.6%	-$662K+1.7%	-$673K-38914.4%	-$2K-100.0%	$3.8M
Financing Cash Flow	$12.3M+163.7%	$4.7M-56.4%	$10.7M-29.1%	$15.1M+38.8%	$10.9M+35123.1%	-$31K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.7M+28.7%	-$2.4M-47.8%	-$1.6M+9.6%	-$1.8M-7.2%	-$1.7M+33.7%	-$2.5M-37.0%	-$1.8M-77.5%	-$1.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.0M
Investing Cash Flow	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0
Financing Cash Flow	$232K	$0+100.0%	-$137K-101.7%	$8.2M+180.0%	$2.9M+762.5%	$339K-59.6%	$838K+476172.2%	$176
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	34.5%+10.6pp	23.9%-10.0pp	33.9%-16.0pp	49.9%	N/A	N/A
Operating Margin	N/A	N/A	-192.2%+1515.1pp	-1707.3%-1171.5pp	-535.9%	N/A
Net Margin	-165.1%+1.8pp	-166.9%+25.2pp	-192.2%+1515.1pp	-1707.3%-1171.5pp	-535.9%	N/A
Return on Equity	-60.8%+22.6pp	-83.4%-17.6pp	-65.7%+139.1pp	-204.9%-66.6pp	-138.3%+13.7pp	-152.1%
Return on Assets	-52.4%+12.5pp	-64.9%-8.6pp	-56.3%+89.1pp	-145.4%-41.1pp	-104.3%+10.3pp	-114.6%
Current Ratio	6.99+2.6	4.41-1.3	5.66+2.8	2.89-0.9	3.78+0.0	3.77
Debt-to-Equity	0.16-0.1	0.28+0.1	0.17-0.2	0.41+0.1	0.330.0	0.33
FCF Margin	-157.1%-5.0pp	-152.1%+27.8pp	-180.0%+1254.0pp	-1434.0%-919.7pp	-514.3%	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	22.5%-13.5pp	36.0%-8.2pp	44.2%+30.3pp	13.9%-27.5pp	41.5%+2.4pp	39.0%+2.7pp	36.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-247.3%-93.1pp	-154.2%-17.1pp	-137.1%+31.1pp	-168.1%+63.5pp	-231.6%-99.0pp	-132.7%+18.3pp	-151.0%
Return on Equity	-43.0%-21.9pp	-21.1%-6.3pp	-14.9%-1.6pp	-13.3%+16.9pp	-30.2%+11.4pp	-41.6%-21.7pp	-20.0%+1.1pp	-21.0%
Return on Assets	-32.5%-14.4pp	-18.1%-5.2pp	-12.9%-1.4pp	-11.5%+11.4pp	-22.9%+7.4pp	-30.3%-14.3pp	-16.0%+0.4pp	-16.4%
Current Ratio	3.12-2.8	5.94-1.0	6.95-0.0	6.99+3.5	3.49+0.4	3.05-2.0	5.07+0.7	4.41
Debt-to-Equity	0.33+0.2	0.17+0.0	0.150.0	0.16-0.2	0.32-0.1	0.38+0.1	0.25-0.0	0.28
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-80.2%

Similar Companies

SHUTTLE PHARMACTCLS HLDGS INC SHPH

$1.7M

Redhill Biopharm RDHL

$4.2M

Sunshine Biopharma Inc SBFM

$4.4M

PRF Technologies Ltd. PRFX

$4.1M

China Pharma CPHI

$23.1M

Frequently Asked Questions

What is Inmed Pharmaceuticals Inc's annual revenue?

Inmed Pharmaceuticals Inc (INM) reported $4.9M in total revenue for fiscal year 2025. This represents a 7.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Inmed Pharmaceuticals Inc's revenue growing?

Inmed Pharmaceuticals Inc (INM) revenue grew by 7.5% year-over-year, from $4.6M to $4.9M in fiscal year 2025.

Is Inmed Pharmaceuticals Inc profitable?

No, Inmed Pharmaceuticals Inc (INM) reported a net income of -$8.2M in fiscal year 2025, with a net profit margin of -165.1%.

What is Inmed Pharmaceuticals Inc's gross margin?

Inmed Pharmaceuticals Inc (INM) had a gross margin of 34.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Inmed Pharmaceuticals Inc's net profit margin?

Inmed Pharmaceuticals Inc (INM) had a net profit margin of -165.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Inmed Pharmaceuticals Inc's return on equity (ROE)?

Inmed Pharmaceuticals Inc (INM) has a return on equity of -60.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Inmed Pharmaceuticals Inc's free cash flow?

Inmed Pharmaceuticals Inc (INM) generated -$7.8M in free cash flow during fiscal year 2025. This represents a -11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Inmed Pharmaceuticals Inc's operating cash flow?

Inmed Pharmaceuticals Inc (INM) generated -$7.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Inmed Pharmaceuticals Inc's total assets?

Inmed Pharmaceuticals Inc (INM) had $15.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Inmed Pharmaceuticals Inc's capital expenditures?

Inmed Pharmaceuticals Inc (INM) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Inmed Pharmaceuticals Inc spend on research and development?

Inmed Pharmaceuticals Inc (INM) invested $2.9M in research and development during fiscal year 2025.

How many shares does Inmed Pharmaceuticals Inc have outstanding?

Inmed Pharmaceuticals Inc (INM) had 2M shares outstanding as of fiscal year 2025.

What is Inmed Pharmaceuticals Inc's current ratio?

Inmed Pharmaceuticals Inc (INM) had a current ratio of 6.99 as of fiscal year 2025, which is generally considered healthy.

What is Inmed Pharmaceuticals Inc's debt-to-equity ratio?

Inmed Pharmaceuticals Inc (INM) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Inmed Pharmaceuticals Inc's return on assets (ROA)?

Inmed Pharmaceuticals Inc (INM) had a return on assets of -52.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Inmed Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Inmed Pharmaceuticals Inc (INM) had $10.7M in cash against an annual operating cash burn of $7.8M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Inmed Pharmaceuticals Inc's Piotroski F-Score?

Inmed Pharmaceuticals Inc (INM) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Inmed Pharmaceuticals Inc's earnings high quality?

Inmed Pharmaceuticals Inc (INM) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Inmed Pharmaceuticals Inc?

Inmed Pharmaceuticals Inc (INM) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.